» Articles » PMID: 24854552

[Expression and Significance of IKBKB in Pulmonary Adenocarcinoma A549 Cells and Its Cisplatin-resistant Variant A549/DDP]

Overview
Date 2014 May 24
PMID 24854552
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Cisplatin-resistance in Lung cancer cells is widespread in the clinical treatment, seriously affecting the effects of the treatment of lung cancer. Therefore, the research of mechanisms of cisplain-resistance has significant meaning for developing new chemotherapeutic drug and solving the cisplain-resistance in clinic treatment. IKBKB is one of the most important catalytic subunits of IKK complexes. It plays an important regulatory role in activation of NF-κB. The aim of this study is to investigate the differential expression of IKBKB gene in human lung adenocarcinoma cells line A549 and the cisplatin-resistant variant A549/DDP and the mechanisms of cisplain-resistance induced by IKBKB gene.

Methods: MTT assay was employed to determine the sensitivity of A549 and A549/DDP cells line to cisplatin and the effect of IKBKB gene on A549 cell lines' sensitivity to cisplatin. The mRNA level of IKBKB was determined by real-time PCR. Dual luciferase reporter gene experiment was employed to determine the activity of the NF-κB. Apoptosis rate of lung adenocarcinoma cells was determined by flow cytometry.

Results: Apoptosis rate and IC50 were significantly different in A549 and A549/DDP cells, the expression of mRNA level of IKBKB gene in A549/DDP was significantly higher than that in A549. Compared with control group, IKBKB gene was able to reduce the cisplain sensitivity of A549 cells. After A549 was transfected with pcDNA3.1/IKBKB plasmid, mRNA level of IKBKB was significantly increased, the sensitivity of cisplain was decreased, the IC50 was increased 2.85 fold, the apoptosis rate was decreased 59%, the activity of NF-κB has been greatly increased.

Conclusions: IKBKB inhibits cisplatin-induced apoptosis via the activation of NF-κB pathway. It will be helpful in the development of new anticancer drug and solving the challenge of cisplatin-resistance.

Citing Articles

MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification.

Liu H, Tang T Sci Rep. 2023; 13(1):19055.

PMID: 37925483 PMC: 10625624. DOI: 10.1038/s41598-023-45774-0.


The mechanism of flavonoids from on inhibiting liver cancer based on experiments and network pharmacology.

Mo J, Tong Y, Ma J, Wang K, Feng Y, Wang L Front Pharmacol. 2023; 14:1049953.

PMID: 36817123 PMC: 9936097. DOI: 10.3389/fphar.2023.1049953.


NETISCE: a network-based tool for cell fate reprogramming.

Marazzi L, Shah M, Balakrishnan S, Patil A, Vera-Licona P NPJ Syst Biol Appl. 2022; 8(1):21.

PMID: 35725577 PMC: 9209484. DOI: 10.1038/s41540-022-00231-y.


MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.

Li Y, Zu L, Wu H, Zhang F, Fan Y, Pan H Thorac Cancer. 2021; 13(3):430-441.

PMID: 34953057 PMC: 8807278. DOI: 10.1111/1759-7714.14278.


An Autophagy-Related Long Non-Coding RNA Prognostic Signature for Patients with Lung Squamous Carcinoma Based on Bioinformatics Analysis.

Liu B, Zhao Y, Yang S Int J Gen Med. 2021; 14:6621-6637.

PMID: 34675625 PMC: 8520473. DOI: 10.2147/IJGM.S331327.

References
1.
Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

2.
Branch P, Masson M, Aquilina G, Bignami M, Karran P . Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene. 2000; 19(28):3138-45. DOI: 10.1038/sj.onc.1203668. View

3.
Zhu Z, Zhu Z, Cai H, Liu Y . Reversion of multidrug resistance by SKI-II in SGC7901/DDP cells and exploration of underlying mechanisms. Asian Pac J Cancer Prev. 2012; 13(2):625-31. DOI: 10.7314/apjcp.2012.13.2.625. View

4.
Jemal A, Tiwari R, Murray T, Ghafoor A, Samuels A, Ward E . Cancer statistics, 2004. CA Cancer J Clin. 2004; 54(1):8-29. DOI: 10.3322/canjclin.54.1.8. View

5.
Duarte V, Han E, Veena M, Salvado A, Suh J, Liang L . Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther. 2010; 9(10):2665-75. PMC: 3004013. DOI: 10.1158/1535-7163.MCT-10-0064. View